Strata Critical Medical, Inc. (SRTA)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $484.11M
Last updated: Nov 17, 2026 at 4:15 PM ET
Strata Critical Medical, Inc. (SRTA) Statistics
Strata Critical Medical (SRTA) has a market cap of $484.11M. Its share count is up 7.06% from a year earlier. Revenue grew 22.73% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $484.11M |
|---|---|
| Latest price (Nov 17, 2026) | $5.24 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.6x and 1.7x.
| P/S Ratio | 1.6x |
|---|---|
| Forward P/S | 1.7x |
| P/B Ratio | 1.7x |
| P/TBV Ratio | 4.0x |
| P/OCF Ratio | 46.6x |
Price Statistics
The stock is up 9.39% over 52 weeks and trades 4.38% above its 50-day average.
| Beta (1Y) | 1.88 |
|---|---|
| 52-Week Change | +9.39% |
| 1-Month Change | +15.42% |
| 3-Month Change | -11.04% |
| 6-Month Change | +0.38% |
| Total Return (1Y) | +9.39% |
| Return vs SPY (1Y) | +7.26% |
| Max Drawdown (1Y) | -33.85% |
| Sharpe Ratio (1Y) | 0.31 |
| Correlation with SPY (1Y) | 0.47 |
| 50-Day Average | $5.02 |
| 200-Day Average | $5.10 |
| 52-Week Range | $3.95 to $6.50 |
| RSI (14 Days) | 51.4 |
| Average Volume (20 Days) | 1.24M |
Financial Position
Current assets cover 2.77x current liabilities.
| Current Ratio | 2.77x |
|---|---|
| Quick Ratio | 2.77x |
Returns and Efficiency
Return on equity is -8.98% over the last 12 months, against a 5-year average of -9.02%.
| Return on Equity (ROE) | -8.98% |
|---|---|
| Return on Assets (ROA) | -7.54% |
| Return on Capital Employed (ROCE) | -6.98% |
| ROE (5Y Average) | -9.02% |
| ROA (5Y Average) | -7.45% |
| ROIC (5Y Average) | -12.41% |
| Asset Turnover | 0.85x |
| Inventory Turnover | 2718.73x |
| Receivables Turnover | 6.52x |
| Cash Conversion Cycle | 29 days |
Scores
SRTA has an Altman Z-Score of 5.54, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.54 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $280.76M over the last 12 months.
| Revenue | $280.76M |
|---|---|
| Revenue Growth (YoY) | +22.73% |
| Gross Profit | $57.82M |
| Operating Income | -$18.62M |
| Pretax Income | -$21.12M |
| Net Income | -$24.81M |
| EBITDA | -$9.02M |
| EBIT | -$19.82M |
| Reported EPS (TTM) | -$0.14 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 84.04% of the $328.88M in total assets.
| Cash and Equivalents | $35.14M |
|---|---|
| Working Capital | $80.02M |
| Shareholder Equity | $276.38M |
| Book Value Per Share | $3.13 |
| Tangible Book Value | $115.63M |
| Tangible Book Per Share | $1.31 |
| Total Assets | $328.88M |
| Total Liabilities | $52.51M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $10.07M of capital spending, operating cash flow left $320.00K of free cash flow.
| Operating Cash Flow | $10.39M |
|---|---|
| Capital Expenditures | $10.07M |
| Free Cash Flow | $320.00K |
| FCF Per Share | $0.00 |
| Depreciation and Amortization | $21.89M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -6.63%, against a 5-year average of -27.91%.
| Gross Margin | 20.59% |
|---|---|
| Operating Margin | -6.63% |
| Pretax Margin | -7.52% |
| Net Margin | -8.84% |
| EBITDA Margin | -3.21% |
| EBIT Margin | -7.06% |
| FCF Margin | 0.11% |
| Gross Margin (5Y Average) | 19.86% |
| Operating Margin (5Y Average) | -27.91% |
| Net Margin (5Y Average) | -22.57% |
Growth
Revenue grew 10.50% a year over 3 years.
| Revenue Growth (3Y CAGR) | +10.50% |
|---|---|
| Revenue Growth (5Y CAGR) | +53.10% |
| Book Value Per Share Growth (2Y CAGR) | +3.85% |
| Tangible Book Per Share Growth (2Y CAGR) | -13.48% |
Dividends and Yields
SRTA does not pay a dividend. Its free cash flow yield is 0.07%.
| FCF Yield | 0.07% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 8 similar companies, SRTA has the 4th highest P/S.
P/S RatioPeer median 1.3x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +4.85%
| P/S Ratio | 1.6x vs 1.3x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +22.73% vs +4.85% median |
Analyst Forecast
Consensus estimates put revenue growth at 28.41% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +28.41% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SRTA
What is SRTA's market cap?
Strata Critical Medical has a market cap of $484.11M.
How many shares of SRTA are outstanding?
Strata Critical Medical has 88.27M shares outstanding. The count is up 7.06% from a year earlier.
Does SRTA pay a dividend?
No. Strata Critical Medical does not pay a dividend.
SRTA pages: Overview, Earnings, Forecast, Financials, Statistics, Competitors